Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Medtronic (NYSE: MDT) announced today that the FDA cleared its Hugo robotic-assisted surgery system for use in urologic surgical procedures.

Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform. | The ...

This device will take time to have a material impact on the company's financial results. Still, Medtronic has a strong business, multiple growth opportunities, and a fantastic dividend program. 10 ...

Medtronic’s Hugo robotic surgery system earns FDA clearance, ending Intuitive’s long-held dominance and reshaping the future of soft-tissue robotics.

The long-awaited FDA clearance sets up a showdown in the surgical robotics market between Medtronic and Intuitive Surgical.

With FDA clearance, the Hugo RAS system is indicated for use in minimally invasive urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy — common procedures that account ...

Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage ...

In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its ...

Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top five robotic surgeons in the U.S. James Porter serves as medical director of ...

Minneapolis-based Medtronic, the world’s largest standalone medical device manufacturer, is developing a new robotic surgical system expected to be released by 2019. Robotically assisted surgery ...